

The highly polymorphic cyclophilin A-binding loop in HIV-1 confers resistance to MxB

Retrovirology

12, 1

DOI: [10.1186/s12977-014-0129-1](https://doi.org/10.1186/s12977-014-0129-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	An HIV-1 capsid binding protein TRIM11 accelerates viral uncoating. <i>Retrovirology</i> , 2016, 13, 72.	0.9	35
2	SUN2 Overexpression Deforms Nuclear Shape and Inhibits HIV. <i>Journal of Virology</i> , 2016, 90, 4199-4214.	1.5	42
3	Accumulation of MxB/Mx2-resistant HIV-1 Capsid Variants During Expansion of the HIV-1 Epidemic in Human Populations. <i>EBioMedicine</i> , 2016, 8, 230-236.	2.7	27
4	Capsid-CPSF6 Interaction Is Dispensable for HIV-1 Replication in Primary Cells but Is Selected during Virus Passage <i>in Vivo</i> . <i>Journal of Virology</i> , 2016, 90, 6918-6935.	1.5	50
5	Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha Interferon-Induced Antiviral Factors. <i>Journal of Virology</i> , 2016, 90, 7469-7480.	1.5	40
6	Oligomerization Requirements for MX2-Mediated Suppression of HIV-1 Infection. <i>Journal of Virology</i> , 2016, 90, 22-32.	1.5	41
7	Interferon but not MxB inhibits foamy retroviruses. <i>Virology</i> , 2016, 488, 51-60.	1.1	23
8	Mechanisms of HIV-1 Control. <i>Current HIV/AIDS Reports</i> , 2017, 14, 101-109.	1.1	16
9	Kaposi's sarcoma-associated herpesvirus polyadenylated nuclear RNA: a structural scaffold for nuclear, cytoplasmic and viral proteins. <i>Nucleic Acids Research</i> , 2017, 45, 6805-6821.	6.5	46
10	Capsid-Dependent Host Factors in HIV-1 Infection. <i>Trends in Microbiology</i> , 2017, 25, 741-755.	3.5	101
11	CryoEM structure of MxB reveals a novel oligomerization interface critical for HIV restriction. <i>Science Advances</i> , 2017, 3, e1701264.	4.7	47
12	Effects of Inner Nuclear Membrane Proteins SUN1/UNC-84A and SUN2/UNC-84B on the Early Steps of HIV-1 Infection. <i>Journal of Virology</i> , 2017, 91, .	1.5	18
13	Role of Innate Genes in HIV Replication. <i>Current Topics in Microbiology and Immunology</i> , 2017, 419, 69-111.	0.7	6
14	Are Evolution and the Intracellular Innate Immune System Key Determinants in HIV Transmission?. <i>Frontiers in Immunology</i> , 2017, 8, 1246.	2.2	28
15	Hijacking of the Ubiquitin/Proteasome Pathway by the HIV Auxiliary Proteins. <i>Viruses</i> , 2017, 9, 322.	1.5	53
16	Cyclophilin A potentiates TRIM5 β inhibition of HIV-1 nuclear import without promoting TRIM5 β binding to the viral capsid. <i>PLoS ONE</i> , 2017, 12, e0182298.	1.1	12
17	ADAR1 and PKR, interferon stimulated genes with clashing effects on HIV-1 replication. <i>Cytokine and Growth Factor Reviews</i> , 2018, 40, 48-58.	3.2	25
18	Naturally Occurring Mutations in HIV-1 CRF01_AE Capsid Affect Viral Sensitivity to Restriction Factors. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 382-392.	0.5	9

#	ARTICLE	IF	CITATIONS
19	HIV-1 capsids from B27/B57+ elite controllers escape Mx2 but are targeted by TRIM5 α , leading to the induction of an antiviral state. <i>PLoS Pathogens</i> , 2018, 14, e1007398.	2.1	25
20	Multiple components of the nuclear pore complex interact with the amino-terminus of MX2 to facilitate HIV-1 restriction. <i>PLoS Pathogens</i> , 2018, 14, e1007408.	2.1	43
21	A compartmentalized type I interferon response in the gut during chronic HIV-1 infection is associated with immunopathogenesis. <i>Aids</i> , 2018, 32, 1599-1611.	1.0	18
22	Role of MxB in Alpha Interferon-Mediated Inhibition of HIV-1 Infection. <i>Journal of Virology</i> , 2018, 92, .	1.5	14
23	Equine MX2 is a restriction factor of equine infectious anemia virus (EIAV). <i>Virology</i> , 2018, 523, 52-63.	1.1	12
24	MXB inhibits murine cytomegalovirus. <i>Virology</i> , 2018, 522, 158-167.	1.1	26
25	Cellular Factors That Regulate Retrovirus Uncoating and Reverse Transcription. , 2018, , 51-112.		1
26	MxB Restricts HIV-1 by Targeting the Tri-hexamer Interface of the Viral Capsid. <i>Structure</i> , 2019, 27, 1234-1245.e5.	1.6	36
27	Multiple Pathways To Avoid Beta Interferon Sensitivity of HIV-1 by Mutations in Capsid. <i>Journal of Virology</i> , 2019, 93, .	1.5	17
28	Small-molecule agents for the treatment of inflammatory bowel disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2034-2041.	1.0	11
29	Human MxB Inhibits the Replication of Hepatitis C Virus. <i>Journal of Virology</i> , 2019, 93, .	1.5	33
30	Novel HIV-1 capsid-targeting small molecules of the PF74 binding site. <i>European Journal of Medicinal Chemistry</i> , 2020, 204, 112626.	2.6	14
31	HIV-1 resists MxB inhibition of viral Rev protein. <i>Emerging Microbes and Infections</i> , 2020, 9, 2030-2045.	3.0	5
32	Laboratory and clinical findings and their association with viral and proviral loads in cats naturally infected with feline leukemia virus. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2020, 71, 101491.	0.7	0
33	MxB impedes the NUP358-mediated HIV-1 pre-integration complex nuclear import and viral replication cooperatively with CPSF6. <i>Retrovirology</i> , 2020, 17, 16.	0.9	16
34	Use of exosomes as vectors to carry advanced therapies. <i>RSC Advances</i> , 2020, 10, 23975-23987.	1.7	21
35	TRIM34 restricts HIV-1 and SIV capsids in a TRIM5 α -dependent manner. <i>PLoS Pathogens</i> , 2020, 16, e1008507.	2.1	39
36	Matrin 3 in neuromuscular disease: physiology and pathophysiology. <i>JCI Insight</i> , 2021, 6, .	2.3	30

#	ARTICLE	IF	CITATIONS
37	Cyclophilin A: a key player for etiological agent infection. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 1365-1377.	1.7	19
38	Human TRIM5 $\hat{\pm}$: Autophagy Connects Cell-Intrinsic HIV-1 Restriction and Innate Immune Sensor Functioning. <i>Viruses</i> , 2021, 13, 320.	1.5	13
40	Viral Suppression of RIPK1-Mediated Signaling. <i>MBio</i> , 2021, 12, e0172321.	1.8	15
41	Human Acute and Chronic Viruses: Host-Pathogen Interactions and Therapeutics. , 2020, , 1-120.		3
45	Anti-HIV lectins and current delivery strategies. <i>AIMS Molecular Science</i> , 2018, 5, 96-116.	0.3	5
46	Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2. <i>ELife</i> , 2018, 7, .	2.8	100
47	MxB sensitivity of HIV-1 is determined by a highly variable and dynamic capsid surface. <i>ELife</i> , 2020, 9, .	2.8	14
48	HIV-1 capsid variability: viral exploitation and evasion of capsid-binding molecules. <i>Retrovirology</i> , 2021, 18, 32.	0.9	17
49	MX2 and HIV-1 Restriction. , 2015, , 1-8.		0
50	MX2 and HIV-1 Restriction. , 2018, , 1420-1427.		0
56	Emerging vaccine nanotechnology: From defense against infection to sniping cancer. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 2206-2223.	5.7	52
57	In silico prediction of HIV-1-host molecular interactions and their directionality. <i>PLoS Computational Biology</i> , 2022, 18, e1009720.	1.5	0
58	Emerging Roles of Cyclophilin A in Regulating Viral Cloaking. <i>Frontiers in Microbiology</i> , 2022, 13, 828078.	1.5	11
59	MxB inhibits long interspersed element type 1 retrotransposition. <i>PLoS Genetics</i> , 2022, 18, e1010034.	1.5	7
61	Secondary Osteoporosis and Metabolic Bone Diseases. <i>Journal of Clinical Medicine</i> , 2022, 11, 2382.	1.0	28
62	Clade-Specific Alterations within the HIV-1 Capsid Protein with Implications for Nuclear Translocation. <i>Biomolecules</i> , 2022, 12, 695.	1.8	3
63	Lectins and lectibodies: potential promising antiviral agents. <i>Cellular and Molecular Biology Letters</i> , 2022, 27, 37.	2.7	20
65	Small extracellular vesicles as key players in cancer development caused by human oncogenic viruses. <i>Infectious Agents and Cancer</i> , 2022, 17, .	1.2	2

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------